Merck to acquire US Biopharma firm SpringWorks Therapeutics for enterprise value of $3.4 billion
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide